2012 119: 1325-1326 doi:10.1182/blood-2011-12-394486
A new target for myeloma therapy
Updated information and services can be found at: http://bloodjournal.hematologylibrary.org/content/119/6/1325.full.html Information about reproducing this article in parts or in its entirety maybe found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml
Blood (printISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.
From bloodjournal.hematologylibrary.org by guest on February 14, 2012. For personal use only.
9 FEBRUARY 2012 I VOLUME 119, NUMBER 6 ● ● ● LYMPHOID NEOPLASIAComment on Azab et al, page 1468
A new target for myeloma therapy ---------------------------------------------------------------------------------------------------------------Rauf Haznedar
˙ GAZI UNIVERSITY MEDICAL SCHOOL
In this issue of Blood, Azab and colleagues demonstrate that PSGL-1 expressed on myeloma cells is involved with regulating tumor cell extravasation, homing, diseaseprogression, and drug resistance.1
Down-regulation of PSGL-1 in MM cells or inhibition of selectin with antibody reversed drug resistance induced by BM stromal cells in mice treated with bortezomib.
ver the past two decades, treatment for multiple myeloma has improved with the use of high-dose melphalan therapy with peripheral blood stem cell support and novel drugs including thalidomide,bortezomib, and lenalidomide. In younger patients, survival now extends beyond 10 years. In elderly myeloma patients, obtaining complete remission has become the goal of therapy with the use of novel drug combinations. Myeloma cell– microenvironment interactions are crucially important in understanding disease biology and pathogenesis.2 After the discovery of IL-6, we have learned that insulin-likegrowth factor-1, vascular endothelial growth factor, and tumor necrosis factor also promote myeloma cell proliferation. Microenvironment bone marrow stroma not only contribute to my-
eloma cell growth and survival, but also produce proangiogenic factors and contribute to drug resistance and bone disease.2,3 Proteasome inhibitors and the immunomodulatory drugs (ImiDs) thalidomide andlenalidomide affect the microenvironment in addition to directly killing myeloma cells. IMiDs enhance immune response to myeloma cells, enhance natural killer cell function, stimulate T-cell proliferation and CD8 T-cell activation, and increase IL-2 and IFN levels.4 Bortezomib supresses the expression of CD49d at mRNA level, down-regulates VLA-4, and may help overcome cell adhesion–mediated drugresistance.5 Bortezomib inhibits ostoclastogenesis and stimulates bone formation. It can be used in combination to treat myeloma bone disease.
Despite these advances, multiple myeloma is still an incurable disease. Myeloma patients, having worse genetic features, have poorer response to therapy and survival is short. Apart from the reported high-risk features, cell adhesion–mediated drug resistanceplays a role in treatment failure. Although the proteasome inhibitor bortezomib helps overcome drug resistance to some extent, we clearly need new approaches. Targeted therapy with monoclonal antibodies has given rise to great hope in hematologic malignancies. We need to develop more effective drugs and more efﬁcient antibodies. Currently targeted therapy with cyclindependent kinases4/6 and VEGF...